HEPARIN INDUCED THROMBOCYTOPENIA IN CARDIOVASCULAR SURGERY. PATHOGENESIS, DIAGNOSTICS AND CORRECTION METHODS
https://doi.org/10.17802/2306-1278-2014-4-95-103
Abstract
The article presents the review of the literature dedicated to the problem of pathogenesis of such a severe complication as the heparin induced thrombocytopenia, clinical implications, methods of its diagnostics and modern management of such patients when performing treatment and diagnostic measures in cardiovascular diseases.
About the Author
A. L. Pirogov
Federal State Budgetary Institution Federal Cardiovascular Surgery Centre, Ministry of Healthcare of the Russian Federation, Chelyabinsk
Russian Federation
Russian Federation
Dr. Med. Sci.
chief freelance cardiologist
Correspondence address:
A. L. Pirogov, 2, Hero of Russia E. N. Rodionov Pr., 454003, Chelyabinsk. Tel.: +7(351) 255-93-67
References
1. Бокерия Л . А ., Чигерин И . Н. Гепарининдуцированная тромбоцитопения (современное состояние проблемы). М.: Изд. НЦССХ им. А. Н. Бакулева, 2007. 96 с.
2. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery / J. C. Vasquez [et al.] // Ann. Thorac. Surg. 2002. Vol. 74 (6). P. 2177–2179.
3. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance / P. Eichler [et al.] // Blood. 2000. Vol. 96 (7). P. 2373–2378.
4. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin / T. E. Warkentin [et al.] // Blood. 2005. Vol. 106 (12). P. 3791–3796.
5. Arepally G. M., Ortel T. L. Clinical practice. Heparininduced thrombocytopenia // N. Engl. J. Med. 2006. Vol. 355 (8). P. 809–817.
6. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia / B. E. Lewis [et al.] // Circulation. 2001. Vol. 103 (14). P. 1838–1843
7. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia / B. E. Lewis [et al.] // Catheter Cardiovasc. Interv. 2002. Vol. 57 (2). P. 177–184.
8. Argatroban anticoagulation in patients with heparininduced thrombocytopenia / B. E. Lewis // Arch. Intern. Med. 2003. Vol. 163 (15). P. 1849–1856.
9. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia / Messmore H. [et al.] // Drug Saf. 2003. Vol. 26 (9). P. 625–41.
10. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention / K. R. Campbell [et al.] // J. Invasive Cardiol. 2000. Vol. 12 (Suppl. F. 14).
11. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass / A. Koster [et al.] // Anesth. Analg. 2003. Vol. 96 (2). P. 383–386 (table of contents).
12. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature / I. Datta [et al.] // J. Trauma Manag. Outcomes. 2010. Vol. 4 (1).
13. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparininduced thrombocytopenia / C. Pouplard [et al.] // Am. J. Clin. Pathol. 1999. Vol. 111 (5). P. 700–706.
14. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass / A. Lillo-Le Louët [et al.] // J. Thromb. Haemost. 2004. Vol. 2 (11). P. 1882–1888.
15. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values / R. C. Gosselin [et al.] // Am. J. Clin. Pathol. 2004. Vol. 121 (4). P. 593–599.
16. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia / B. E. Lewis [et al.] // Chest. 2006. Vol. 129 (6) P. 1407–1416.
17. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia / B. Tardy-Poncet [et al.] // Chest. 1999. Vol. 115 (6). P. 1616–1620.
18. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia / T. H. Kiser [et al.] // Pharmacotherapy. 2005. Vol. 25 (12). P. 1736–1745.
19. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia / B. Lobo [et al.] // Thromb. Haemost. 2008. Vol. 99 (1). P. 208–214.
20. Fondaparinux thromboprophylaxis-associated heparininduced thrombocytopenia syndrome complicated by arterial thrombotic stroke / M. Salem [et al.] // Thromb. Haemost. 2010. Vol. 104 (5). P. 10711072.
21. Gallus A. S., Coghlan D. W. Heparin pentasaccharide // Curr. Opin. Hematol. 2002. Vol. 9 (5). P. 422–429.
22. GEHT-HIT StudyGroup. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin / B. Tardy [et al.] // Blood. 2006. Vol. 108 (5). P. 1492–1496.
23. Gender imbalance and risk factor interaction in heparininduced thrombocytopenia / T. E. Warkentin [et al.] // Blood. 2006. Vol. 108 (9). P. 2937–2941.
24. Greinacher A., Lubenow N., Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia // Circulation. 2003. Vol. 108 (17). P. 2062–2065.
25. Greinacher A., Warkentin T. E. Heparin-induced thrombocytopenia. New York, N. Y: Marcel Dekker, 2004. 627 р.
26. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen / A. Greinacher [et al.] // Thromb. Haemost. 1994. Vol. 71 (2). P. 247–251.
27. Heparin-induced thrombocytopenia / D. B. Brieger [et al.] // J. Am. Coll. Cardiol. 1998. Vol. 31 (7). P. 1449–1459.
28. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin / T. E. Warkentin [et al.] // N. Engl. J. Med. 1995. Vol. 332 (20). P. 1330–1335.
29. Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy / E. A. Natelson [et al.] // Ann. Intern. Med. 1969. Vol. 71 (6). P. 1121–1125.
30. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes / A. Greinacher [et al.] // J. Thromb. Haemost. 2007. Vol. 5 (8). P. 1666–1673.
31. http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20883s4lbl.pdf.
32. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020807s011lbl.pdf.
33. Ibbotson T., Perry C. M. Danaparoid: a review of its use in thromboembolic and coagulation disorders // Drugs. 2002. Vol. 62 (15). P. 2283–2314.
34. IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics / S. Motokawa [et al.] // BMC. Musculoskelet Disord. 2011. Vol. 12 (22).
35. Impact of the patient population on the risk for heparininduced thrombocytopenia / T. E. Warkentin [et al.] // Blood. 2000. Vol. 96 (5). P. 1703–1708.
36. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations / S. D. Gitlin [et al.] // J. Vasc. Surg. 1998. Vol. 27 (3). P. 568–575.
37. Jang I. K., Hursting M. J. When heparins promote thrombosis: review of heparin-induced thrombocytopenia // Circulation. 2005. Vol. 111 (20). P. 2671–2683.
38. Kelton J. G., Warkentin T. E. Heparin-induced thrombocytopenia: a historical perspective // Blood. 2008. Vol. 112 (7). P. 2607–2616.
39. Lepirudin for anticoagulation in patients with heparininduced thrombocytopenia treated with continuous renal replacement therapy / A. Gajra [et al.] // Am. J. Hematol. 2007. Vol. 82 (5). P. 391–393.
40. Martel N., Lee J., Wells P. S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis // Blood. 2005. Vol. 106 (8). P. 2710–2715.
41. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications-a review. Arch. Pathol / F. Fabris [et al.] // Lab. Med. 2000. Vol. 124 (11). P. 1657–1666.
42. Prechel М . М ., Walenga М . J. Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia // Thrombosis Journal. 2013. Vol. 11 (7).
43. Pötzsch B., Klövekorn W. P., Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia // N. Engl. J. Med. 2000. Vol. 343 (7). P. 515.
44. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4) / O. Meyer [et al.] // Lancet. 1999. Vol. 354 (9189). P. 1525–1526.
45. Rhodes G. R., Dixon R. H., Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations // Surg. Gynecol. Obstet. 1973. Vol. 136 (3). P. 409–416.
46. Rice L. Evolving management strategies for heparininduced thrombocytopenia // Semin. Hematol. 2005. Vol. 42 (Suppl 3). P. 15–21.
47. Rivaroxaban an oral, direct Factor Xa inhibitor has potential for the management of patients with heparin-induced thrombocytopenia / J. M. Walenga [et al.] // Br. J. Haematol. 2008. Vol. 143 (1). P. 92–99.
48. Roque Pifarre. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997. P. 487–500.
49. Rota E., Bazzan M., Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT) // Thromb. Haemost. 2008. Vol. 99 (4). P. 779–781.
50. Shantsila E., Lip G. Y., Chong B. H. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management // Chest. 2009. Vol. 135 (6). P. 1651–1664.
51. Skin necrosis following subcutaneous heparin injection / A.W. Mar [et al.] // Australas. J. Dermatol. 1995. Vol. 36 (4). P. 201–203.
52. Tapson V. F. Acute pulmonary embolism // N. Engl. J. Med. 2008. Vol. 358 (10). P. 1037–1052.
53. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia / T. E. Warkentin [et al.] // Ann. Intern. Med. 1997. Vol. 127 (9). P. 804–812.
54. Tomer A., Masalunga C., Abshire T. C. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation // Am. J. Hematol. 1999. Vol. 61 (1). P. 53–61.
55. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) / T. E. Warkentin [et al.] // Chest. 2008. Vol. 133 (6 Suppl.). P. 340–380.
56. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines / L. Linkins [et al.] // Chest. 2012. Vol. 141 (2 suppl.). P. 495–530.
57. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia / N. L. Whitlatch [et al.] // Blood. 2010. Vol. 116 (10). P. 1761–1766.
58. Warkentin T. E., Greinacher A. So, does low-molecularweight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? // Chest. 2007. Vol. 132 (4). P. 1108–1110.
59. Warkentin T. E., Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery // Ann. Thorac. Surg. 2003. Vol. 76 (6). P. 2121–2131.
60. Warkentin T. E., Kelton J. G. A 14-year study of heparininduced-thrombocytopenia // Am. J. Med. 1996. Vol. 101 (5). P. 502–507.
61. Warkentin T. E., Kelton J. G. Temporal aspects of heparin-induced thrombocytopenia // N. Engl. J. Med. 2001. Vol. 344 (17). P. 1286–1292.
62. Warkentin T. E., Kelton J. G. Delayed-onset heparininduced thrombocytopenia and thrombosis // Ann. Intern. Med. 2001. Vol. 135 (7). P. 502–506.
63. Warkentin T. E., Sheppard J. A. Testing for heparininduced thrombocytopenia antibodies» // Transfus. Med. Rev. 2006. Vol. 20 (4). P. 259–272.
64. Weismann R. E., Tobin R. W. Arterial embolism occurring during systemic heparin therapy // AMA Arch. Surg. 1958. Vol. 76 (2). P. 219–225 (discussion 225–7).
65. Yeh R. W., Jang I. K. Argatroban: update // Am. Heart J. 2006. Vol. 151 (6). P. 1131–1138.
Review
For citations:
Pirogov A.L. HEPARIN INDUCED THROMBOCYTOPENIA IN CARDIOVASCULAR SURGERY. PATHOGENESIS, DIAGNOSTICS AND CORRECTION METHODS. Complex Issues of Cardiovascular Diseases. 2014;(4):95-103. (In Russ.) https://doi.org/10.17802/2306-1278-2014-4-95-103
Views:
689
